Risk of Reactivation of Hepatitis B Virus (HBV) and Tuberculosis (TB) and Complications of Hepatitis C Virus (HCV) Following Tocilizumab Therapy: A Systematic Review to Inform Risk Assessment in the COVID-19 Era

Risk of Reactivation of Hepatitis B Virus (HBV) and Tuberculosis (TB) and Complications of Hepatitis C Virus (HCV) Following Tocilizumab Therapy: A Systematic Review to Inform Risk Assessment in the COVID-19 Era

Objectives: Tocilizumab (TCZ), an IL-6 receptor antagonist, is used in the treatment of severe COVID-19 caused by infection with SARS-CoV-2. However, unintended consequences of TCZ therapy include reactivation of tuberculosis (TB) or hepatitis B virus (HBV), and worsening of hepatitis C virus (HCV)....

Full description

Bibliographic Details
Main Authors: Cori Campbell, Monique I. Andersson, M. Azim Ansari, Olivia Moswela, Siraj A. Misbah, Paul Klenerman, Philippa C. Matthews
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-08-01
Series:Frontiers in Medicine
Subjects:
tocilizumab
biologic
SARS-CoV-2
COVID-19
infection
reactivation
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2021.706482/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2021.706482/full

Similar Items